Literature DB >> 14770183

Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation.

Kimberly Stegmaier1, Kenneth N Ross, Sierra A Colavito, Shawn O'Malley, Brent R Stockwell, Todd R Golub.   

Abstract

Chemical genomics involves generating large collections of small molecules and using them to modulate cellular states. Despite recent progress in the systematic synthesis of structurally diverse compounds, their use in screens of cellular circuitry is still an ad hoc process. Here, we outline a general, efficient approach called gene expression-based high-throughput screening (GE-HTS) in which a gene expression signature is used as a surrogate for cellular states, and we describe its application in a particular setting: the identification of compounds that induce the differentiation of acute myeloid leukemia cells. In screening 1,739 compounds, we identified 8 that reliably induced the differentiation signature and, furthermore, yielded functional evidence of bona fide differentiation. The results indicate that GE-HTS may be a powerful, general approach for chemical screening.

Entities:  

Mesh:

Year:  2004        PMID: 14770183     DOI: 10.1038/ng1305

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  111 in total

1.  Multiplex mRNA assay using electrophoretic tags for high-throughput gene expression analysis.

Authors:  Huan Tian; Liching Cao; Yuping Tan; Stephen Williams; Lili Chen; Tracy Matray; Ahmed Chenna; Sean Moore; Vincent Hernandez; Vivian Xiao; Mengxiang Tang; Sharat Singh
Journal:  Nucleic Acids Res       Date:  2004-09-08       Impact factor: 16.971

2.  Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery.

Authors:  Hairi Li; Hongyan Zhou; Dong Wang; Jinsong Qiu; Yu Zhou; Xiangqiang Li; Michael G Rosenfeld; Sheng Ding; Xiang-Dong Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-06       Impact factor: 11.205

3.  Transcriptomine, a web resource for nuclear receptor signaling transcriptomes.

Authors:  Scott A Ochsner; Christopher M Watkins; Apollo McOwiti; Xueping Xu; Yolanda F Darlington; Michael D Dehart; Austin J Cooney; David L Steffen; Lauren B Becnel; Neil J McKenna
Journal:  Physiol Genomics       Date:  2012-07-10       Impact factor: 3.107

4.  Use of big data in drug development for precision medicine.

Authors:  Rosa S Kim; Nicolas Goossens; Yujin Hoshida
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-04-28

Review 5.  Exploring biology with small organic molecules.

Authors:  Brent R Stockwell
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

Review 6.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

Review 7.  High throughput screening for neurodegeneration and complex disease phenotypes.

Authors:  Hemant Varma; Donald C Lo; Brent R Stockwell
Journal:  Comb Chem High Throughput Screen       Date:  2008-03       Impact factor: 1.339

8.  Gene expression-based screening identifies microtubule inhibitors as inducers of PGC-1alpha and oxidative phosphorylation.

Authors:  Zoltan Arany; Bridget K Wagner; Yanhong Ma; Jessica Chinsomboon; Dina Laznik; Bruce M Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-17       Impact factor: 11.205

9.  A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.

Authors:  Daniel J Deangelo; Donna Neuberg; Philip C Amrein; Jacob Berchuck; Martha Wadleigh; L Andres Sirulnik; Ilene Galinsky; Todd Golub; Kimberly Stegmaier; Richard M Stone
Journal:  Leuk Res       Date:  2013-11-05       Impact factor: 3.156

10.  The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia.

Authors:  Hubo Li; Brenton G Mar; Huadi Zhang; Rishi V Puram; Francisca Vazquez; Barbara A Weir; William C Hahn; Benjamin Ebert; David Pellman
Journal:  Blood       Date:  2016-10-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.